An open clinical trial to test the effect of Chirayata [Swertia purpurascens Wall]in the management of Non-Alcoholic Fatty Liver Disease

An open randomized clinical trial to evaluate the effect of Chirayata [Swertia purpurascens Wall]in the management of Non-Alcoholic Fatty Liver Disease - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084560

Enrollment

Registered

2025-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having altered serum liver enzymes levels defined as serum AST and ALT more than normal but less than 2 times upper normal limit and ultrasonographical evidence of Non -Alcoholic Fatty Liver Disease.

Exclusion criteria

Exclusion criteria: Patients having serum liver level enzymes (AST and ALT)levels more than 2 times of upper normal limit . Patients having hepatitis B and C ,liver malignancy or having any other comorbidity. Patients consuming alcohol .

Design outcomes

Primary

Measure	Time frame
To lower the altered serum liver enzyme levels AST AND ALT.Timepoint: 3 months	—

Secondary

Measure	Time frame
To assess the clinical safety of Chirayata [Swertia purpurascens Wall]in the patients of Non-Alcoholic Fatty Liver DiseaseTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Archna Kumari

drmsony@gmail.com9816842425

Outcome results